Posted by

Inspirational patient helps unveil King's College London as a Centre of Excellence

Posted by
21 Jul 2010

Blood cancer patient Daisy Turner, 21 from Ipswich, was the special guest at the unveiling of a plaque at King’s College Hospital, naming it as a Leukaemia & Lymphoma Research Centre of Excellence.

King’s College London, which includes King’s College Hospital, has been recognised for its
world-class research into adult leukaemia and rare blood disorders such as the myelodysplastic syndromes (MDS) and aplastic anaemia. Leukaemia & Lymphoma Research currently has more than £4 million invested in 14 research projects at the Centre.

Daisy, who received life saving treatment at King’s, unveiled the plaque with King’s College Hospital’s CEO Tim Smart and her doctor and Leukaemia & Lymphoma Research scientist Professor Ghulam Mufti.

All our researchers at King’s College London work closely with doctors at King’s College Hospital to ensure that any breakthroughs in diagnosis and treatment benefit blood cancer patients across London as soon as possible.

Daisy, who was diagnosed with MDS at the young age of 16, was referred to King’s College Hospital in 2005 and placed under the immediate care of Professor Mufti who is a world expert in MDS.

Professor Mufti said: “We’re delighted to have been named as one of Leukaemia & Lymphoma Research’s Centres of Excellence. Treatments for blood cancers have advanced rapidly in recent years and the pace of research is really exciting. The support of charities such as Leukaemia & Lymphoma Research is vital to keep this going until we achieve the ultimate aim of eradicating leukaemia and allied blood cancers.”

The unveiling of the Centre of Excellence, at King’s College Hospital on Denmark Hill, is part of Leukaemia & Lymphoma Research’s plans to focus investment in leading research institutions across the UK.  

Other groundbreaking projects taking place at King’s include research into the causes of a particularly aggressive form of leukaemia called acute promyelocytic leukaemia (APL), which is particularly difficult to treat.

Cathy Gilman, Chief Executive of Leukaemia & Lymphoma Research, said: “King’s has an outstanding record of developing new drugs and treatment methods and quickly making them available to blood cancer patients who need them most. It is this achievement that truly makes it a ‘Centre of Excellence’.”

Read more about Daisy's story here.


Make a donation

I would like to give...